Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.88 EUR
Change Today +0.15 / 2.62%
Volume 120.5K
As of 11:35 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (THR) Snapshot

Open
€5.79
Previous Close
€5.73
Day High
€6.08
Day Low
€5.73
52 Week High
04/25/14 - €24.00
52 Week Low
04/1/15 - €4.75
Market Cap
212.3M
Average Volume 10 Days
175.6K
EPS TTM
€-1.42
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THROMBOGENICS NV (THR)

Related News

No related news articles were found.

thrombogenics nv (THR) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (THR) Details

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes ophthalmic and oncology medicines in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat various disorders, such as cancer, age-related macular degeneration, retinopathy, and inflammation; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc. to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

120 Employees
Last Reported Date: 04/4/15
Founded in 1991

thrombogenics nv (THR) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €690.0K
Executive Director
Total Annual Compensation: --
Executive Director and Member of Audit Commit...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

thrombogenics nv (THR) Key Developments

ThromboGenics and VIB Launch New Oncology Company, Oncurious NV

ThromboGenics NV announced the foundation of Oncurious NV, a new oncology company that will develop TB-403 for the treatment of pediatric brain tumors. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. VIB will become a shareholder alongside ThromboGenics in this new oncology venture. ThromboGenics will be the majority shareholder. TB-403 is a humanized monoclonal antibody against placental growth factor. PlGF is expressed in several types of cancer, including medulloblastoma. High expression of the PlGF receptor neuropilin 1 has been shown to correlate with poor overall survival. Medulloblastoma is a rare, life-threatening brain tumor that mainly affects children. Treatment with TB-403 in relevant animal models for medulloblastoma has demonstrated beneficial effects on tumor growth and survival. The antibody can potentially be used in other pediatric cancer indications, including neuroblastoma. Oncurious now plans to start a Phase I/IIa program with TB-403 in medulloblastoma patients. Enrollment of the first patient is expected for the end of 2015. The favorable safety profile of TB-403 has already been demonstrated in clinical trials in patients with other diseases. BioInvent International AB will act as a co-development partner for this oncology project. ThromboGenics has retained the exclusive license for use of TB-403 in ophthalmic indications.

ThromboGenics NV Announces Positive Topline Results from OASIS Study

ThromboGenics NV announced positive topline results from its OASIS study with JETREA(R) (ocriplasmin). The OASIS study is a randomized, sham controlled, double masked study that followed up patients for 24 months post injection. The study was designed to provide long term controlled efficacy and safety data for JETREA(R) in patients being treated for symptomatic vitreomacular adhesion (sVMA). The OASIS study is the first controlled study with JETREA(R) of its kind since the results of the pivotal Phase III program were announced in 2011. The study includes 24 month follow up data, the period patients have been studied post treatment with this novel medicine. The key findings of the study were 41.7% of patients treated with JETREA(R) achieved VMA resolution at Day 28 post injection compared with only 6.2% of patients who received a sham injection (p<0.001); and the JETREA(R) safety profile in this 24 month follow up study was consistent with the drug's overall safety profile as known from the approved label. No new safety events were identified. The OASIS data compare favorably with the results from the pivotal Phase III program with JETREA(R) where VMA resolution was seen in 26.5% of patients at Day 28 post injection. In the Phase III program 10.1% of patients treated with a placebo injection achieved VMA resolution (p<0.001). The OASIS data show the importance of improved patient selection in generating higher rates of VMA resolution with JETREA(R). Recent real world data have confirmed that access to more advanced diagnostic technology such as SD-OCT, has enabled retina physicians to improve patient selection. As a result they have been able to select patients with focal VMA and an absence of Epiretinal Membrane (ERM), two criteria which have been shown to lead to better treatment outcomes with JETREA(R).

ThromboGenics NV Reports Consolidated Earnings Results for the Year December 31, 2014

ThromboGenics NV reported consolidated earnings results for the year December 31, 2014. For the year, the group reported sales of €13.8 million compared to €112.8 million, operating loss of €52.7 million compared to operating results of €25.5 million, loss before income tax of €51.0 million compared to result before income tax of €26.4 million, loss attributable equity holders of the company of €51.1 million or €1.42 per basic and diluted share compared to profit attributable equity holders of the company of €26.4 million or €0.71 per diluted share, net used in operating activities of €46.6 million compared to net from operating activities of €25.7 million, acquisition of intangible assets of €12,000 compared to €3.4 million and acquisition of property, plant and equipment of €0.6 million compared to €2.2 million for the last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THR:BB €5.88 EUR +0.15

THR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THR.
View Industry Companies
 

Industry Analysis

THR

Industry Average

Valuation THR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.4x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.